Testosterone replacement therapy improved function without PSA recurrence in prostate cancer survivors with hypogonadism.
Findings seen over three months in men with low-grade prostate cancer, hypogonadism treated with radical prostatectomy.
KPG-121, a novel cereblon modulator, in patients with metastatic castration resistant prostate cancer: Results of a phase I multiple ascending dose study. Baseline PSMA PET/CT as a predictive ...
It is difficult to escape a genitourinary malignancies session at any major oncology meeting these days without hearing a proclamation that the technetium-99 (Tc99) bone scan is dead. The triumphant ...
CIRT leads to temporary urinary function decline, normalizing within three months and stable for five years. Prostate volume decreases significantly without ADT, remaining reduced for five years. T ...
Prostate-specific antigen (PSA) blood testing likely reduces the risk of death from prostate cancer, found a new review ...
In a randomized clinical trial, Mass General Brigham researchers found testosterone replacement therapy also improved quality of life for men who had undergone radical prostatectomy ...
A new blood test could help doctors identify whether a treatment for advanced prostate cancer is failing weeks earlier than ...
Although blood test reduces deaths by two for every 1,000 men screened, many could face unnecessary treatment ...
Researchers with the James P. Allison Institute™ at The University of Texas MD Anderson Cancer Center have discovered a new ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results